Effectiveness of tipranavir versus darunavir as a salvage therapy in HIV-1 treatment-experienced patients | Zendy

Juan Carlos Domínguez-Hermosillo | Zendy; José Antonio MataMarín | Zendy; Norma Estela Herrera-González | Zendy; Marcelino Chávez-García | Zendy; Gloria Huerta-García | Zendy; Nohemí Núñez-Rodríguez | Zendy; José Gerardo García-Gámez | Zendy; Anai Jiménez-Romero | Zendy; Jesús GaytánMartínez | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effectiveness of tipranavir versus darunavir as a salvage therapy in HIV-1 treatment-experienced patients

Author(s) -

Juan Carlos Domínguez-Hermosillo,

José Antonio MataMarín,

Norma Estela Herrera-González,

Marcelino Chávez-García,

Gloria Huerta-García,

Nohemí Núñez-Rodríguez,

José Gerardo García-Gámez,

Anai Jiménez-Romero,

Jesús GaytánMartínez

Publication year - 2016

Publication title -

the journal of infection in developing countries

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.322

H-Index - 49

eISSN - 2036-6590

pISSN - 1972-2680

DOI - 10.3855/jidc.6629

Subject(s) - darunavir , medicine , ritonavir , interquartile range , enfuvirtide , salvage therapy , viral load , raltegravir , regimen , population , protease inhibitor (pharmacology) , gastroenterology , virology , human immunodeficiency virus (hiv) , immunology , antiretroviral therapy , chemotherapy , environmental health , antigen , gp41 , epitope

Although both tipranavir (TPV) and darunavir (DRV) represent important options for the management of patients with multi-protease inhibitor (PI)-resistant human immunodeficiency virus (HIV), currently there are no studies comparing the effectiveness and safety of these two drugs in the Mexican population. The aim of this study was to compare the effectiveness of TPV versus DRV as a salvage therapy in HIV-1 treatment-experienced patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research